INMB

SEC source: 0001213900-21-036352 · ownership.xml · nonDerivative · entry 1

Tesi Raymond Joseph · CIK 0001767280 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,535,284

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $20.00 to $20.04, inclusive. The Reporting Person undertakes to provide to Inmune Bio, Inc., any security holder of Inmune Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the range set forth above.

SEC source: 0001213900-21-034006 · ownership.xml · derivative · entry 1

ALLEN MARCIA · CIK 0001109769 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,025

Underlying: Common Stock · 19,025 shares

Expires 2031-06-21

F1 · shares: Each Option represents a right to receive one share of common stock of INmune Bio, Inc.

F2 · derivative.exercise_date: Options granted pursuant to the Company's 2021 Stock Incentive Plan. These Options vest on a pro rata quarterly basis over three years such that all options to purchase the 19,025 shares will have vested on the third anniversary of the grant date.

SEC source: 0001213900-21-034014 · ownership.xml · derivative · entry 1

Moss David J · CIK 0001421930 · CFO, Treasurer & Secretary · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,663

Underlying: Common Stock · 70,663 shares

Expires 2031-06-21

F1 · shares: Each Option represents a right to receive one share of common stock of INmune Bio, Inc.

F2 · derivative.exercise_date: Options granted pursuant to 2021 Stock Incentive Plan. Twenty-five percent of the Option will vest 12 months from the date of grant and thereafter the remaining unvested Option will become vested and exercisable pro rata on a monthly basis over three (3) years (1/36 per month) until the Option is 100% vested which shall occur on the four-year anniversary of the date of grant.

SEC source: 0001213900-21-034008 · ownership.xml · derivative · entry 1

Baracchini Edgardo Jr · CIK 0001291972 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,025

Underlying: Common Stock · 19,025 shares

Expires 2031-06-21

F1 · shares: Each Option represents a right to receive one share of common stock of INmune Bio, Inc.

F2 · derivative.exercise_date: Options granted pursuant to the Company's 2021 Stock Incentive Plan. These Options vest on a pro rata quarterly basis over three years such that all options to purchase the 19,025 shares will have vested on the third anniversary of the grant date.

SEC source: 0001213900-21-034018 · ownership.xml · derivative · entry 1

Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,663

Underlying: Common Stock · 70,663 shares

Expires 2031-06-22

F1 · shares: Each Option represents a right to receive one share of common stock of INmune Bio, Inc.

F2 · derivative.exercise_date: Options granted pursuant to 2021 Stock Incentive Plan. Twenty-five percent of the Option will vest 12 months from the date of grant and thereafter the remaining unvested Option will become vested and exercisable pro rata on a monthly basis over three (3) years (1/36 per month) until the Option is 100% vested which shall occur on the four-year anniversary of the date of grant.

SEC source: 0001213900-21-034016 · ownership.xml · derivative · entry 1

Schroeder Timothy j · CIK 0001767226 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,025

Underlying: Common Stock · 19,025 shares

Expires 2031-06-21

F1 · shares: Each Option represents a right to receive one share of common stock of INmune Bio, Inc.

F2 · derivative.exercise_date: Options granted pursuant to the Company's 2021 Stock Incentive Plan. These Options vest on a pro rata quarterly basis over three years such that all options to purchase the 19,025 shares will have vested on the third anniversary of the grant date.

SEC source: 0001213900-21-034012 · ownership.xml · derivative · entry 1

Juda Scott · CIK 0001767084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,025

Underlying: Common Stock · 19,025 shares

Expires 2031-06-21

F1 · shares: Each Option represents a right to receive one share of common stock of INmune Bio, Inc.

F2 · derivative.exercise_date: Options granted pursuant to the Company's 2021 Stock Incentive Plan. These Options vest on a pro rata quarterly basis over three years such that all options to purchase the 19,025 shares will have vested on the third anniversary of the grant date.

SEC source: 0001213900-21-034010 · ownership.xml · derivative · entry 1

Ganjei James Kelly · CIK 0001767300 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,025

Underlying: Common Stock · 19,025 shares

Expires 2031-06-21

F1 · shares: Each Option represents a right to receive one share of common stock of INmune Bio, Inc.

F2 · derivative.exercise_date: Options granted pursuant to the Company's 2021 Stock Incentive Plan. These Options vest on a pro rata quarterly basis over three years such that all options to purchase the 19,025 shares will have vested on the third anniversary of the grant date.

SEC source: 0001213900-21-032529 · ownership.xml · nonDerivative · entry 1

Schroeder Timothy j · CIK 0001767226 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 136,667

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $19.00 to $19.01, inclusive. The Reporting Person undertakes to provide to Inmune Bio, Inc., any security holder of Inmune Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the range set forth above.

F3 · ownership.nature: These shares of Common Stock are held by CTI Holdings, a company of which Mr. Schroeder is the majority shareholder. Mr. Schroeder has voting and investment control over these shares.

SEC source: 0001415889-21-002991 · form4-06142021_010635.xml · nonDerivative · entry 1

Xencor Inc · CIK 0001326732 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

F1 · kind: On October 3, 2017, INmune Bio Inc. ("INmune") entered into a license agreement ("Xencor License Agreement") with Xencor, Inc. ("Xencor"). In connection with the Xencor License Agreement, INmune granted Xencor an option to purchase an additional number of shares of common stock equal to 10% of the fully diluted company shares immediately following such purchase (the "Option"). On June 10, 2021, INmune entered into an Option Cancellation Agreement with Xencor, pursuant to which Xencor agreed to cancel the Option and terminate certain other rights in exchange for these shares and $15,000,000. The number of shares was determined by dividing $3.3 million by the closing price of INmune's common stock on June 10, 2021.

F1 · price: On October 3, 2017, INmune Bio Inc. ("INmune") entered into a license agreement ("Xencor License Agreement") with Xencor, Inc. ("Xencor"). In connection with the Xencor License Agreement, INmune granted Xencor an option to purchase an additional number of shares of common stock equal to 10% of the fully diluted company shares immediately following such purchase (the "Option"). On June 10, 2021, INmune entered into an Option Cancellation Agreement with Xencor, pursuant to which Xencor agreed to cancel the Option and terminate certain other rights in exchange for these shares and $15,000,000. The number of shares was determined by dividing $3.3 million by the closing price of INmune's common stock on June 10, 2021.

SEC source: 0001213900-21-032300 · ownership.xml · nonDerivative · entry 1

Schroeder Timothy j · CIK 0001767226 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 146,667

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $17.00 to $17.04, inclusive. The Reporting Person undertakes to provide to Inmune Bio, Inc., any security holder of Inmune Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the range set forth above.

F3 · ownership.nature: These shares of Common Stock are held by CTI Holdings, a company of which Mr. Schroeder is the majority shareholder. Mr. Schroeder has voting and investment control over these shares.

SEC source: 0001415889-21-004280 · form4a-09082021_040901.xml · nonDerivative · entry 1

Xencor Inc · CIK 0001326732 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,777,533

F1 · kind: On October 3, 2017, INmune Bio Inc. ("INmune") entered into a license agreement ("Xencor License Agreement") with Xencor, Inc. ("Xencor"). In connection with the Xencor License Agreement, INmune granted Xencor an option to purchase an additional number of shares of common stock equal to 10% of the fully diluted company shares immediately following such purchase (the "Option"). On June 10, 2021, INmune entered into an Option Cancellation Agreement with Xencor, pursuant to which Xencor agreed to cancel the Option and terminate certain other rights in exchange for these shares and $15,000,000. The number of shares was determined by dividing $3.3 million by the closing price of INmune's common stock on June 10, 2021.

F2 · shares: On June 14, 2021, Xencor filed a Form 4 which inadvertently reported that Xencor acquired 192,532 shares of common stock in the Option Cancellation Transaction. As reported in this amendment, Xencor actually acquired 192,533 shares of common stock in the Option Cancellation Transaction. The original Form 4 also inadvertently indicated that Xencor beneficially owned 1,777,532 shares of common stock following the Option Cancellation Transaction, but Xencor actually beneficially owned 1,777,533 shares of common stock.

F1 · price: On October 3, 2017, INmune Bio Inc. ("INmune") entered into a license agreement ("Xencor License Agreement") with Xencor, Inc. ("Xencor"). In connection with the Xencor License Agreement, INmune granted Xencor an option to purchase an additional number of shares of common stock equal to 10% of the fully diluted company shares immediately following such purchase (the "Option"). On June 10, 2021, INmune entered into an Option Cancellation Agreement with Xencor, pursuant to which Xencor agreed to cancel the Option and terminate certain other rights in exchange for these shares and $15,000,000. The number of shares was determined by dividing $3.3 million by the closing price of INmune's common stock on June 10, 2021.

F2 · balance_after: On June 14, 2021, Xencor filed a Form 4 which inadvertently reported that Xencor acquired 192,532 shares of common stock in the Option Cancellation Transaction. As reported in this amendment, Xencor actually acquired 192,533 shares of common stock in the Option Cancellation Transaction. The original Form 4 also inadvertently indicated that Xencor beneficially owned 1,777,532 shares of common stock following the Option Cancellation Transaction, but Xencor actually beneficially owned 1,777,533 shares of common stock.

SEC source: 0001415889-21-004279 · form4a-09082021_040901.xml · nonDerivative · entry 1

Xencor Inc · CIK 0001326732 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,777,533

F1 · kind: On October 3, 2017, INmune Bio Inc. ("INmune") entered into a license agreement ("Xencor License Agreement") with Xencor, Inc. ("Xencor"). In connection with the Xencor License Agreement, INmune granted Xencor an option to purchase an additional number of shares of common stock equal to 10% of the fully diluted company shares immediately following such purchase (the "Option"). On June 10, 2021, INmune entered into an Option Cancellation Agreement with Xencor, pursuant to which Xencor agreed to cancel the Option and terminate certain other rights in exchange for these shares and $15,000,000. The number of shares was determined by dividing $3.3 million by the closing price of INmune's common stock on June 10, 2021.

F2 · shares: On June 14, 2021, Xencor filed a Form 4 which inadvertently reported that Xencor acquired 192,532 shares of common stock in the Option Cancellation Transaction. As reported in this amendment, Xencor actually acquired 192,533 shares of common stock in the Option Cancellation Transaction. The original Form 4 also inadvertently indicated that Xencor beneficially owned 1,777,532 shares of common stock following the Option Cancellation Transaction, but Xencor actually beneficially owned 1,777,533 shares of common stock.

F1 · price: On October 3, 2017, INmune Bio Inc. ("INmune") entered into a license agreement ("Xencor License Agreement") with Xencor, Inc. ("Xencor"). In connection with the Xencor License Agreement, INmune granted Xencor an option to purchase an additional number of shares of common stock equal to 10% of the fully diluted company shares immediately following such purchase (the "Option"). On June 10, 2021, INmune entered into an Option Cancellation Agreement with Xencor, pursuant to which Xencor agreed to cancel the Option and terminate certain other rights in exchange for these shares and $15,000,000. The number of shares was determined by dividing $3.3 million by the closing price of INmune's common stock on June 10, 2021.

F2 · balance_after: On June 14, 2021, Xencor filed a Form 4 which inadvertently reported that Xencor acquired 192,532 shares of common stock in the Option Cancellation Transaction. As reported in this amendment, Xencor actually acquired 192,533 shares of common stock in the Option Cancellation Transaction. The original Form 4 also inadvertently indicated that Xencor beneficially owned 1,777,532 shares of common stock following the Option Cancellation Transaction, but Xencor actually beneficially owned 1,777,533 shares of common stock.

SEC source: 0001213900-21-019674 · ownership.xml · nonDerivative · entry 1

Schroeder Timothy j · CIK 0001767226 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 156,667

F1 · kind: The sales reported in this Form 4 were effected in the open market outside of a 10b5 plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $11.59 to $12.47, inclusive. The Reporting Person undertakes to provide to Inmune Bio, Inc., any security holder of Inmune Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the range set forth above.

F3 · ownership.nature: These shares of Common Stock are held by CTI Holdings, a company of which Mr. Schroeder is the majority shareholder. Mr. Schroeder has voting and investment control over these shares.

SEC source: 0001213900-21-003482 · ownership.xml · derivative · entry 1

ALLEN MARCIA · CIK 0001109769 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,975

Underlying: Common Stock · 15,975 shares

Expires 2031-01-18

F1 · shares: Each Option represents a right to receive one share of common stock of INmune Bio, Inc.

F3 · price: Not applicable

F2 · derivative.exercise_date: Options granted pursuant to 2019 Stock Incentive Plan. Options shall vest on a pro rata quarterly basis over three years such that all options to purchase the 15,975 shares will have vested on the third anniversary of the grant date.

SEC source: 0001213900-21-003479 · ownership.xml · derivative · entry 1

Moss David J · CIK 0001421930 · CFO, Treasurer & Secretary · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,337

Underlying: Common Stock · 59,337 shares

Expires 2031-01-18

F1 · shares: Each Option represents a right to receive one share of common stock of INmune Bio, Inc.

F3 · price: Not applicable

F2 · derivative.exercise_date: Options granted pursuant to 2017 Stock Incentive Plan. Twenty-five percent of the Option will vest 12 months from the date of grant and thereafter the remaining unvested Option will become vested and exercisable pro rata on a monthly basis over three (3) years (1/36 per month) until the Option is 100% vested which shall occur on the four-year anniversary of the date of grant.

SEC source: 0001213900-21-003478 · ownership.xml · derivative · entry 1

Baracchini Edgardo Jr · CIK 0001291972 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,975

Underlying: Common Stock · 15,975 shares

Expires 2031-01-18

F1 · shares: Each Option represents a right to receive one share of common stock of INmune Bio, Inc.

F3 · price: Not applicable

F2 · derivative.exercise_date: Options granted pursuant to 2019 Stock Incentive Plan. Options shall vest on a pro rata quarterly basis over three years such that all options to purchase the 15,975 shares will have vested on the third anniversary of the grant date.

SEC source: 0001213900-21-003485 · ownership.xml · derivative · entry 1

Schroeder Timothy j · CIK 0001767226 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,975

Underlying: Common Stock · 15,975 shares

Expires 2031-01-18

F1 · shares: Each Option represents a right to receive one share of common stock of INmune Bio, Inc.

F3 · price: Not applicable

F2 · derivative.exercise_date: Options granted pursuant to 2019 Stock Incentive Plan. Options shall vest on a pro rata quarterly basis over three years such that all options to purchase the 15,975 shares will have vested on the third anniversary of the grant date.

SEC source: 0001213900-21-003484 · ownership.xml · derivative · entry 1

Juda Scott · CIK 0001767084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,975

Underlying: Common Stock · 15,975 shares

Expires 2031-01-18

F1 · shares: Each Option represents a right to receive one share of common stock of INmune Bio, Inc.

F3 · price: Not applicable

F2 · derivative.exercise_date: Options granted pursuant to 2019 Stock Incentive Plan. Options shall vest on a pro rata quarterly basis over three years such that all options to purchase the 15,975 shares will have vested on the third anniversary of the grant date.

SEC source: 0001213900-21-003483 · ownership.xml · derivative · entry 1

Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,337

Underlying: Common Stock · 59,337 shares

Expires 2031-01-18

F1 · shares: Each Option represents a right to receive one share of common stock of INmune Bio, Inc.

F2 · derivative.exercise_date: Options granted pursuant to 2019 Stock Incentive Plan Twenty-five percent of the Option will vest 12 months from the date of grant and thereafter the remaining unvested Option will become vested and exercisable pro rata on a monthly basis over three (3) years (1/36 per month) until the Option is 100% vested which shall occur on the four-year anniversary of the date of grant.

SEC source: 0001213900-21-003481 · ownership.xml · derivative · entry 1

Ganjei James Kelly · CIK 0001767300 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,975

Underlying: Common Stock · 15,975 shares

Expires 2031-01-18

F1 · shares: Each Option represents a right to receive one share of common stock of INmune Bio, Inc.

F3 · price: Not applicable

F2 · derivative.exercise_date: Options granted pursuant to 2019 Stock Incentive Plan. Options shall vest on a pro rata quarterly basis over three years such that all options to purchase the 15,975 shares will have vested on the third anniversary of the grant date.

SEC source: 0001104659-20-008253 · tv537330_4.xml · nonDerivative · entry 1

Powers Linda F · CIK 0001289624 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 210,000

SEC source: 0001213900-19-024961 · ownership.xml · derivative · entry 1

Moss David J · CIK 0001421930 · CFO, Treasurer & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 700,000

Underlying: Common Stock · 300,000 shares

Expires not disclosed

F1 · shares: Each Option represents a right to receive one share of common stock of INmune Bio, Inc.

F2 · derivative.exercise_date: Vests pro rata on a monthly basis over three years (1/36) such that the Option will be fully vested three years from the date of grant.

F2 · derivative.expiration_date: Vests pro rata on a monthly basis over three years (1/36) such that the Option will be fully vested three years from the date of grant.

SEC source: 0001213900-19-024949 · ownership.xml · derivative · entry 1

Baracchini Edgardo Jr · CIK 0001291972 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,000

Underlying: Common Stock · 108,000 shares

Expires not disclosed

F1 · shares: Each Option represents a right to receive one share of common stock of INmune Bio, Inc.

F2 · derivative.exercise_date: Vests one third (1/3) on the first anniversary of the date of grant and pro rata on a monthly basis over two years (1/24) thereafter, such that the Option will be fully vested three years from the date of grant.

F2 · derivative.expiration_date: Vests one third (1/3) on the first anniversary of the date of grant and pro rata on a monthly basis over two years (1/24) thereafter, such that the Option will be fully vested three years from the date of grant.

SEC source: 0001213900-19-024954 · ownership.xml · derivative · entry 1

Juda Scott · CIK 0001767084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 216,000

Underlying: Common Stock · 108,000 shares

Expires not disclosed

F1 · shares: Each Option represents a right to receive one share of common stock of INmune Bio, Inc.

F2 · derivative.exercise_date: Vests pro rata on a monthly basis over three years (1/36) such that the Option will be fully vested three years from the date of grant.

F2 · derivative.expiration_date: Vests pro rata on a monthly basis over three years (1/36) such that the Option will be fully vested three years from the date of grant.

SEC source: 0001213900-19-024968 · ownership.xml · derivative · entry 1

Schroeder Timothy j · CIK 0001767226 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 216,000

Underlying: Common Stock · 108,000 shares

Expires not disclosed

F1 · shares: Each Option represents a right to receive one share of common stock of INmune Bio, Inc.

F2 · derivative.exercise_date: Vests pro rata on a monthly basis over three years (1/36) such that the Option will be fully vested three years from the date of grant.

F2 · derivative.expiration_date: Vests pro rata on a monthly basis over three years (1/36) such that the Option will be fully vested three years from the date of grant.

SEC source: 0001213900-19-024971 · ownership.xml · derivative · entry 1

Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 700,000

Underlying: Common Stock · 300,000 shares

Expires not disclosed

F1 · shares: Each Option represents a right to receive one share of common stock of INmune Bio, Inc.

F2 · derivative.exercise_date: Vests pro rata on a monthly basis over three years (1/36) such that the Option will be fully vested three years from the date of grant.

F2 · derivative.expiration_date: Vests pro rata on a monthly basis over three years (1/36) such that the Option will be fully vested three years from the date of grant.

SEC source: 0001213900-19-024956 · ownership.xml · derivative · entry 1

Lowdell Mark William · CIK 0001767037 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 580,000

Underlying: Common Stock · 180,000 shares

Expires not disclosed

F1 · shares: Each Option represents a right to receive one share of common stock of INmune Bio, Inc.

F2 · derivative.exercise_date: Vests pro rata on a monthly basis over three years (1/36) such that the Option will be fully vested three years from the date of grant.

F2 · derivative.expiration_date: Vests pro rata on a monthly basis over three years (1/36) such that the Option will be fully vested three years from the date of grant.

SEC source: 0001213900-19-024951 · ownership.xml · derivative · entry 1

Ganjei James Kelly · CIK 0001767300 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 216,000

Underlying: Common Stock · 108,000 shares

Expires not disclosed

F1 · shares: Each Option represents a right to receive one share of common stock of INmune Bio, Inc.

F2 · derivative.exercise_date: Vests pro rata on a monthly basis over three years (1/36) such that the Option will be fully vested three years from the date of grant.

F2 · derivative.expiration_date: Vests pro rata on a monthly basis over three years (1/36) such that the Option will be fully vested three years from the date of grant.

SEC source: 0001213900-19-017904 · ownership.xml · nonDerivative · entry 1

Lowdell Mark William · CIK 0001767037 · Chief Scientific Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,506,251

F1 · shares: The Reporting Person purchased an aggregate of 2,918 shares of the Registrant's common stock on September 11, 2019 in an open market transaction.

SEC source: 0001213900-19-016514 · ownership.xml · nonDerivative · entry 2

Juda Scott · CIK 0001767084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,500

F1 · shares: The Reporting Person purchased 2,500 shares of the Issuer's common stock in an open market transaction on August 20, 2019 and 2,5000 shares of the Issuer's common stock in an open market transaction on August 21, 2019.

F2 · balance_after: The Reporting Person's shares are held by Fossick Capital LP ("Fossick"), a limited partnership. The Reporting Person holds all voting and dispositive control over the Issuer's shares of common stock held by Fossick.

SEC source: 0001213900-19-016455 · ownership.xml · nonDerivative · entry 6

Moss David J · CIK 0001421930 · CFO, Treasurer & Secretary · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,223,417

F1 · shares: The Reporting Person purchased an aggregate of 3,000 shares of the Registrant's common stock on August 20, 2019 in six open market transactions.

SEC source: 0001213900-19-016455 · ownership.xml · nonDerivative · entry 5

Moss David J · CIK 0001421930 · CFO, Treasurer & Secretary · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,223,041

F1 · shares: The Reporting Person purchased an aggregate of 3,000 shares of the Registrant's common stock on August 20, 2019 in six open market transactions.

SEC source: 0001213900-19-016455 · ownership.xml · nonDerivative · entry 4

Moss David J · CIK 0001421930 · CFO, Treasurer & Secretary · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,222,805

F1 · shares: The Reporting Person purchased an aggregate of 3,000 shares of the Registrant's common stock on August 20, 2019 in six open market transactions.

SEC source: 0001213900-19-016455 · ownership.xml · nonDerivative · entry 3

Moss David J · CIK 0001421930 · CFO, Treasurer & Secretary · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,222,733

F1 · shares: The Reporting Person purchased an aggregate of 3,000 shares of the Registrant's common stock on August 20, 2019 in six open market transactions.

SEC source: 0001213900-19-016455 · ownership.xml · nonDerivative · entry 2

Moss David J · CIK 0001421930 · CFO, Treasurer & Secretary · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,220,733

F1 · shares: The Reporting Person purchased an aggregate of 3,000 shares of the Registrant's common stock on August 20, 2019 in six open market transactions.

SEC source: 0001213900-19-016455 · ownership.xml · nonDerivative · entry 1

Moss David J · CIK 0001421930 · CFO, Treasurer & Secretary · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,220,494

F1 · shares: The Reporting Person purchased an aggregate of 3,000 shares of the Registrant's common stock on August 20, 2019 in six open market transactions.

SEC source: 0001213900-19-016453 · ownership.xml · nonDerivative · entry 11

Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,540,933

F1 · shares: The Reporting Person purchased an aggregate of 2,000 shares of the Registrant's common stock on August 20, 2019 in eleven open market transactions.

SEC source: 0001213900-19-016453 · ownership.xml · nonDerivative · entry 10

Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,539,933

F1 · shares: The Reporting Person purchased an aggregate of 2,000 shares of the Registrant's common stock on August 20, 2019 in eleven open market transactions.

SEC source: 0001213900-19-016453 · ownership.xml · nonDerivative · entry 9

Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,539,833

F1 · shares: The Reporting Person purchased an aggregate of 2,000 shares of the Registrant's common stock on August 20, 2019 in eleven open market transactions.

SEC source: 0001213900-19-016453 · ownership.xml · nonDerivative · entry 8

Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,539,733

F1 · shares: The Reporting Person purchased an aggregate of 2,000 shares of the Registrant's common stock on August 20, 2019 in eleven open market transactions.

SEC source: 0001213900-19-016453 · ownership.xml · nonDerivative · entry 7

Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,539,633

F1 · shares: The Reporting Person purchased an aggregate of 2,000 shares of the Registrant's common stock on August 20, 2019 in eleven open market transactions.

SEC source: 0001213900-19-016453 · ownership.xml · nonDerivative · entry 6

Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,539,533

F1 · shares: The Reporting Person purchased an aggregate of 2,000 shares of the Registrant's common stock on August 20, 2019 in eleven open market transactions.

SEC source: 0001213900-19-016453 · ownership.xml · nonDerivative · entry 5

Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,539,433

F1 · shares: The Reporting Person purchased an aggregate of 2,000 shares of the Registrant's common stock on August 20, 2019 in eleven open market transactions.

SEC source: 0001213900-19-016453 · ownership.xml · nonDerivative · entry 4

Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,539,333

F1 · shares: The Reporting Person purchased an aggregate of 2,000 shares of the Registrant's common stock on August 20, 2019 in eleven open market transactions.

SEC source: 0001213900-19-016453 · ownership.xml · nonDerivative · entry 3

Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,539,233

F1 · shares: The Reporting Person purchased an aggregate of 2,000 shares of the Registrant's common stock on August 20, 2019 in eleven open market transactions.

SEC source: 0001213900-19-016453 · ownership.xml · nonDerivative · entry 2

Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,539,133

F1 · shares: The Reporting Person purchased an aggregate of 2,000 shares of the Registrant's common stock on August 20, 2019 in eleven open market transactions.

SEC source: 0001213900-19-016453 · ownership.xml · nonDerivative · entry 1

Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,539,033

F1 · shares: The Reporting Person purchased an aggregate of 2,000 shares of the Registrant's common stock on August 20, 2019 in eleven open market transactions.

SEC source: 0001213900-19-016514 · ownership.xml · nonDerivative · entry 1

Juda Scott · CIK 0001767084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

F1 · shares: The Reporting Person purchased 2,500 shares of the Issuer's common stock in an open market transaction on August 20, 2019 and 2,5000 shares of the Issuer's common stock in an open market transaction on August 21, 2019.

F2 · balance_after: The Reporting Person's shares are held by Fossick Capital LP ("Fossick"), a limited partnership. The Reporting Person holds all voting and dispositive control over the Issuer's shares of common stock held by Fossick.

SEC source: 0001213900-19-015380 · ownership.xml · nonDerivative · entry 3

Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,538,933

F1 · shares: The Reporting Person purchased an aggregate of 2,000 shares of the Registrant's common stock on August 9, 2019 in two open market transactions.